BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) — Market Cap & Net Worth
Market Cap & Net Worth: BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has a market capitalization of $2.18 Billion ($2.18 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6030 globally and #1879 in its home market, demonstrating a 5.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioCryst Pharmaceuticals Inc's stock price $8.92 by its total outstanding shares 254162660 (254.16 Million). Review BCRX current and long-term liabilities to assess the company's total debt and financial obligations.
BioCryst Pharmaceuticals Inc Market Cap History: 2015 to 2026
BioCryst Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $2.62 Billion to $2.27 Billion (0.23% CAGR).
Index Memberships
BioCryst Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.09% | #145 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #660 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.13% | #94 of 263 |
Weight: BioCryst Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioCryst Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioCryst Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.27x
BioCryst Pharmaceuticals Inc's market cap is 2.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.51x
BioCryst Pharmaceuticals Inc's market cap is 7.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.61 Billion | $26.35 Million | -$55.14 Million | 61.05x | N/A |
| 2017 | $1.25 Billion | $25.19 Million | -$65.78 Million | 49.55x | N/A |
| 2018 | $2.05 Billion | $20.65 Million | -$101.25 Million | 99.31x | N/A |
| 2019 | $876.86 Million | $48.84 Million | -$108.90 Million | 17.96x | N/A |
| 2020 | $1.89 Billion | $17.81 Million | -$182.81 Million | 106.31x | N/A |
| 2021 | $3.52 Billion | $157.17 Million | -$184.06 Million | 22.40x | N/A |
| 2022 | $2.92 Billion | $270.83 Million | -$247.12 Million | 10.77x | N/A |
| 2023 | $1.52 Billion | $331.41 Million | -$226.54 Million | 4.59x | N/A |
| 2024 | $1.91 Billion | $450.71 Million | -$88.88 Million | 4.24x | N/A |
| 2025 | $1.98 Billion | $874.84 Million | $263.86 Million | 2.27x | 7.51x |
Competitor Companies of BCRX by Market Capitalization
Companies near BioCryst Pharmaceuticals Inc in the global market cap rankings as of June 17, 2026.
Key companies related to BioCryst Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
BioCryst Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, BioCryst Pharmaceuticals Inc's market cap moved from $2.62 Billion to $ 2.27 Billion, with a yearly change of 0.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.27 Billion | +14.36% |
| 2025 | $1.98 Billion | +3.72% |
| 2024 | $1.91 Billion | +25.54% |
| 2023 | $1.52 Billion | -47.82% |
| 2022 | $2.92 Billion | -17.11% |
| 2021 | $3.52 Billion | +85.91% |
| 2020 | $1.89 Billion | +115.94% |
| 2019 | $876.86 Million | -57.25% |
| 2018 | $2.05 Billion | +64.36% |
| 2017 | $1.25 Billion | -22.43% |
| 2016 | $1.61 Billion | -38.66% |
| 2015 | $2.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of BioCryst Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.18 Billion USD |
| MoneyControl | $2.18 Billion USD |
| MarketWatch | $2.18 Billion USD |
| marketcap.company | $2.18 Billion USD |
| Reuters | $2.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more